Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00465595 · ClinicalTrials.gov registry record · Phase 2
Psychopharmacology of Psilocybin in Cancer Patients
A Phase 2 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
NCT00465595: Completed Phase 2 study, sponsored by Johns Hopkins University.
NCT00465595 is a Phase 2 study that has completed, run by Johns Hopkins University. The registered enrollment target is 56 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00465595, a Phase 2 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
Study Summary
This research is being done to study the psychological effects of psilocybin in cancer patients. Psilocybin is a naturally occurring substance found in some mushrooms that some cultures have used for centuries in religious practices.
Interventions
- DRUG psilocybin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2007-04 |
| Est. Completion | 2016-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00465595
The ClinicalTrials.gov registry entry for NCT00465595 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which psilocybin is the first listed.
NCT00465595 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00465595 about?
NCT00465595 is a clinical study titled "Psychopharmacology of Psilocybin in Cancer Patients". This research is being done to study the psychological effects of psilocybin in cancer patients. Psilocybin is a naturally occurring substance found in some mushrooms that some cultures have used for centuries in religious practices.
What is the current status of trial NCT00465595?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2007-04. Estimated completion is 2016-12.
What interventions are being tested in trial NCT00465595?
The interventions under investigation include: psilocybin (DRUG).
Who is sponsoring clinical trial NCT00465595?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.